The SHP2 protein is a Protein tyrosine phosphates (PTPs) protein family, it catalyze the dephosphorylation of phosphotyrosine residues in protein substrates and play a critical roles in regulating intracellular signal transduction and is responsible for controlling cell growth, differentiation, motility, and metabolism. Whereas, Shp2 has non-receptor PTP containing two N-terminal Src homology 2 (SH2) domains, a PTP domain, and a C-terminal tail. The SHP2 adopts an autoinhibited conformation in its basal state, whereby the N-terminal SH2 domain interacts with the PTP domain and blocks access to the catalytic site. The phosphorylated proteins bind to the SH2 domains of SHP2 and activate the dephosphorylation, which imparts down regulation of RTK-dependent signaling leads to activate oncogenes. Hence, The Shp2-PTPs interaction in physiological processes and that modulation of their enzymatic activity may constitute a therapeutic approach for the treatment of cancer. In the present work we have designed the four sulpho tyrosine based unnatural amino acid libraries through the Insilico modeling, to demonstrate the utility of, Phenyl sulfoaceticacid (PSAA) based Cap-group (a novel sulpho-Tyrosine Mimic) incorporated with novel N-heterocyclic based unnatural amino acid as a Spacer in Library-1, n-Dioxothiazolidene spacer in Library-2, n-pyridazine spacer in library-3 and n-imidazole spacer in library-4 respectively, which was development for novel anti cancerous Shp2-inhibitors, resulted in the five most potential ligand such as Ligand-1a &1b, 2a, 4a & 4b has shown to significant anti-cancerous shp2 inhibitor activity when compared with standard ligand SHP099.

Many of this treatments for Breast cancer (BC-carcinoma), including surgery, radiation, and chemotherapy, haven't been effective in diminishing mortality rates, but bacterial mediated Antibody-immunotoxins has become one in all the best approaches to cancer treatment. Under these exceeding background, the present review, based on increasing mini report on bacterial mediated immunotoxins for breast cancer treatment. Various methodology suggest that, antibody therapies has been an central component in the association of malignant disease. Antibodies be capable of block the tumour growth factors or their specificity receptors and activate the immunological attack on the tumour microenvironment especially in breast cancer cells leads to tumor regression, and are used to deliver payloads such as radioisotopes, cytotoxic drugs or toxins. Immunotoxins are a new class of antitumour agents consisting of tumour selective ligands (generally mono clonal antibodies) linked to highly toxic protein molecules such as non-pathogenic bacterial species or programmed bacteria and take the advantage of the exquisite specificity of antibodies to selectively target drug delivery and the potency of toxins to kill the target cells. Currently, the attenuated bacteria as antitumor agents and vectors for gene directed enzyme prodrug or antibody conjugate therapy or immunotoxin have emerged as potential strategies.

No abstract